Naseem A Jaffrani MD FACC, FSCAI

Cardiology•Alexandria, LA

Cardiac Electrophysiology, Interventional Cardiology

Alexandria Cardiology Clinic

Join to View Full Profile

501 Medical Center DrSuite 250Alexandria, LA 71301
Phone+1 318-473-4613
Fax+1 318-445-7129

Education & Training

Chicago Medical School/Rosalind Franklin University of Medicine & ScienceFellowship, Cardiovascular Disease, 1997
Chicago Medical School/Rosalind Franklin University of Medicine & ScienceResidency, Internal Medicine, 1994
Chicago Medical School/Rosalind Franklin University of Medicine & ScienceInternship, Internal Medicine, 1991 - 1992
Sind Medical CollegeClass of 1989

Certifications & Licensure

LA State Medical License 1997 - 2026
SC State Medical License 2015 - 2015
AZ State Medical License 1997 - 2000
IL State Medical License 1991 - 1999
WI State Medical License 1993 - 1995
American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Clinical Trials

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure Start of enrollment: 2012 Jul 01
Completed
Phase 3
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 Start of enrollment: 2020 Oct 09
Completed
Phase 2
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Start of enrollment: 2021 Nov 23
ACTIVE_NOT_RECRUITING
PHASE3
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors Start of enrollment: 2020 Jan 27
Active, not recruiting
Not Applicable
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen Start of enrollment: 2023 Mar 13
COMPLETED
PHASE2
Roles: Contact
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Start of enrollment: 2024 Apr 30
RECRUITING
PHASE3
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Start of enrollment: 2024 Mar 05
RECRUITING
PHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. Start of enrollment: 2023 Mar 09
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

27 citations
An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.
Michael J Koren, Fatima Rodriguez, Cara East, Peter P Toth, Veena Watwe
Journal of the American College of Cardiology. 2024-05-21
9 citations
Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.
Alex D Hakim, Mustafa Awili, Hollis R O'Neal, Omar Siddiqi, Naseem Jaffrani
Clinical and Experimental Immunology. 2023-10-13
24 citations
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a po...
Subodh Verma, Nitish K. Dhingra, Javed Butler, Stefan D. Anker, João Pedro Ferreira
The Lancet. Diabetes & Endocrinology. 2021-11-30

Professional Memberships

American College of Cardiology - ACC
Fellow
Society of Coronary Angiography & Intervention
Fellow

Other Languages

Hindi, Urdu